Related Experiment Videos
Coffee consumption and risk of incident gout in men: a prospective study
Hyon K Choi1, Walter Willett, Gary Curhan
1Arthritis Research Centre of Canada, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. hchoi@partners.org
Objective:
Coffee is one of the most widely consumed beverages in the world and may affect the risk of gout via various mechanisms. We prospectively evaluated the relationship between coffee intake and the risk of incident gout in a large cohort of men.
Methods:
Over a 12-year period, we studied 45,869 men with no history of gout at baseline. Intake of coffee, decaffeinated coffee, tea, and total caffeine was assessed every 4 years through validated questionnaires. We used a supplementary questionnaire to ascertain whether participants met the American College of Rheumatology survey criteria for gout.
Results:
We documented 757 confirmed incident cases of gout. Increasing coffee intake was inversely associated with the risk of gout. The multivariate relative risks (RRs) for incident gout according to coffee consumption categories (0, <1, 1-3, 4-5, and > or = 6 cups per day) were 1.00, 0.97, 0.92, 0.60 (95% confidence interval [95% CI] 0.41-0.87), and 0.41 (95% CI 0.19-0.88), respectively (P for trend = 0.009). For decaffeinated coffee, the multivariate RRs according to consumption categories (0, <1, 1-3, and > or = 4 cups per day) were 1.00, 0.83, 0.67 (95% CI 0.54-0.82), and 0.73 (95% CI 0.46-1.17), respectively (P for trend = 0.002). Total caffeine from all sources and tea intake were not associated with the risk of gout.
Conclusion:
These prospective data suggest that long-term coffee consumption is associated with a lower risk of incident gout.
Related Concept Videos
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Cancer Prevention
Some...
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Bioavailability Study Design: Healthy Subjects Versus Patients
Hypertension III: Clinical Manifestations and Diagnostic Studies